Short answer
Stereotaxis, Inc. (STXS) filed an 8-K current report with the SEC on July 9, 2026 reporting Item 3.02 (Unregistered Sales of Equity Securities), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Robocath acquisition closed July 7, 2026, with Stereotaxis issuing 1,469,485 shares plus warrants for 4,575,143 shares.
Stereotaxis, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 3.02 · Unregistered Sales of Equity Securities
- Robocath acquisition closed July 7, 2026, with Stereotaxis issuing 1,469,485 shares plus warrants for 4,575,143 shares
- Pre-funded warrants carry a par-value exercise price and expire July 7, 2031, creating substantial potential dilution
- 225,000 additional shares issued to Robocath’s financial advisor as partial success-fee payment
- Earnout consideration could add up to $25.0 million in shares, warrants, or cash, depending on performance targets and adjustments
- Acquisition-related equity issuance capped at 19.9% of pre-issuance shares without stockholder approval; securities issued under private-placement exemptions
Item 7.01 · Regulation FD Disclosure
- Standard Regulation FD disclaimer limiting Exchange Act liability for the disclosure
- No substantive business, financial, or operational information in the provided excerpt
Item 8.01 · Other Events
- Robocath acquisition completed July 7, 2026 for approximately $20 million in cash and common stock
- Transaction expands Stereotaxis’ strategic footprint through Robocath ownership
- Resale registration statement required for shares issued as acquisition consideration
- Registration expected to cover shares tied to regulatory and commercial milestones, creating potential dilution overhang
Item EX-99.1 · Exhibit EX-99.1
- Acquisition of Robocath completed July 9, 2026, converting the previously announced transaction into an operating integration
- Expanded platform across electrophysiology, interventional cardiology, and neurointerventions, broadening Stereotaxis’s addressable market
- Robocath’s R-One has CE and NMPA certifications and is used in Europe and China, providing geographic and regulatory footholds
- R-One achieved more than 98% technical procedure success with no major adverse cardiovascular events in a meta-analysis
- Investor focus shifts to integration execution, commercialization, and contingent payments tied to regulatory and commercial milestones
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Stereotaxis, Inc. 8-K filings
Get the next STXS 8-K as it lands
Follow STXS for push alerts, or ask the research agent what this filing means.